Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $30.4 million.

  • X4 Pharmaceuticals' Net Cash Flow rose 16091.95% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year increase of 5935.05%. This contributed to the annual value of -$43.6 million for FY2024, which is 9064.21% down from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Net Cash Flow is $30.4 million, which was up 16091.95% from -$1.2 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Net Cash Flow high stood at $53.1 million for Q2 2024, and its period low was -$52.8 million during Q3 2023.
  • For the 5-year period, X4 Pharmaceuticals' Net Cash Flow averaged around -$6.2 million, with its median value being -$15.5 million (2025).
  • Per our database at Business Quant, X4 Pharmaceuticals' Net Cash Flow skyrocketed by 65430.6% in 2022 and then tumbled by 26150.88% in 2023.
  • Over the past 5 years, X4 Pharmaceuticals' Net Cash Flow (Quarter) stood at $5.5 million in 2021, then surged by 654.31% to $41.5 million in 2022, then tumbled by 178.24% to -$32.5 million in 2023, then decreased by 27.7% to -$41.5 million in 2024, then surged by 173.37% to $30.4 million in 2025.
  • Its Net Cash Flow was $30.4 million in Q3 2025, compared to -$1.2 million in Q2 2025 and -$15.5 million in Q1 2025.